Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Angiomax: Phase IIIb data

    The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Angiomax ( Angiox - EU) bivalirudin Business: Cardiovascular Molecular target: Thrombin (Factor IIa) (F2) …

    Published on 3/30/2015
  • Atu027: Preliminary Phase IIa data

    Silence Therapeutics plc (LSE:SLN), London, U.K. Product: Atu027 Business: Cancer Molecular target: Protein kinase N3 (PKN3) Description: Liposomal small interfering RNA (siRNA) formulation targeting protein kinase N3 (…

    Published on 3/30/2015
  • BI 655066: Phase II data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: BI 655066 Business: Autoimmune Molecular target: Interleukin-23 (IL-23) Description: Humanized IgG1 mAb that binds and neutralizes the p19 subunit of IL-23 …

    Published on 3/30/2015
  • Brodalumab: Additional Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Brodalumab (KHK4827) (formerly AMG 827) Business: …

    Published on 3/30/2015
  • CERC-301: Phase II data

    Cerecor Inc., Baltimore, Md. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: CERC-301, MK-0657 Business: Neurology Molecular target: NMDA receptor NR2B subtype (GRIN2B) (NR2B) (GluN2B) Description: Small …

    Published on 3/30/2015
  • Cosentyx secukinumab: Additional Phase IIIb data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Cosentyx secukinumab (formerly AIN457) Business: Autoimmune Molecular target: Interleukin-17A (IL-17A) Description: Human IgG1 mAb targeting IL-17A …

    Published on 3/30/2015
  • CRLX101: Additional Phase Ib/IIa data

    Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. Calando Pharmaceuticals Inc., Pasadena, Calif. Cerulean Pharma Inc. (NASDAQ:CERU), Cambridge, Mass. Product: CRLX101 (formerly IT-101) Business: Cancer Molecular …

    Published on 3/30/2015
  • Danoprevir: Phase II data

    Ascletis Pharmaceuticals Co. Ltd., Hangzhou, China Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Danoprevir (ITMN-191, RG7227, ASC08) (formerly R7227) Business: Infectious Molecular target: HCV NS3/4A …

    Published on 3/30/2015
  • DCVax-Brain: Clinical trial data

    Northwest Biotherapeutics Inc. (NASDAQ:NWBO), Bethesda, Md. Product: DCVax-Brain (DCVax-L) Business: Cancer Molecular target: Not applicable Description: Autologous dendritic cells treated ~ex vivo with glioblastoma …

    Published on 3/30/2015
  • Emricasan: Phase II data

    Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), San Diego, Calif. Product: Emricasan (PF-3491390, IDN-6556, PF-03491390) Business: Hepatic Molecular target: Caspases Description: Pan-caspase protease inhibitor Indication: …

    Published on 3/30/2015
  • Esketamine: Interim Phase III data

    Auris Medical Holding AG (NASDAQ:EARS), Zug, Switzerland Product: Esketamine (AM-101) Business: Other Molecular target: NMDA receptor Description: Intratympanicly injected non-competitive antagonist of NMDA receptors …

    Published on 3/30/2015
  • GFT505: Phase IIb data

    Genfit S.A. (Euronext:GNFT), Loos, France Product: GFT505 Business: Hepatic Molecular target: Peroxisome proliferation activated receptor (PPAR) Description: Dual peroxisome proliferation activated receptor (PPAR) alpha…

    Published on 3/30/2015
  • HTX-011: Phase I data

    Heron Therapeutics Inc. (NASDAQ:HRTX), Redwood City, Calif. Product: HTX-011 Business: Neurology Molecular target: NA Description: Long-activing formulation of the local anesthetic bupivacaine in combination with the …

    Published on 3/30/2015
  • ISIS-ANGTPL3Rx: Phase I data

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ISIS-ANGTPL3Rx Business: Endocrine/Metabolic Molecular target: Angiopoietin-like 3 (ANGPTL3) Description: Antisense inhibitor of angiopoietin-like 3 (…

    Published on 3/30/2015
  • Kalydeco ivacaftor: Phase II data

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Royalty Pharma, New York, N.Y. Product: Kalydeco ivacaftor (VX-770) Business: Pulmonary Molecular target: Cystic fibrosis transmembrane conductance regulator (…

    Published on 3/30/2015
  • Keytruda pembrolizumab: Phase III data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Keytruda pembrolizumab (MK-3475) (formerly lambrolizumab) Business: Cancer Molecular target: Programmed cell death 1 (PD-1) (PDCD1) (CD279) Description: …

    Published on 3/30/2015
  • NGM282: Phase II data

    NGM Biopharmaceuticals Inc., South San Francisco, Calif. Product: NGM282 Business: Hepatic Molecular target: Fibroblast growth factor 19 (FGF19) Description: Engineered form of fibroblast growth factor 19 (FGF19) …

    Published on 3/30/2015
  • Obeticholic acid: Additional Phase II data

    Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), New York, N.Y. Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Obeticholic acid (OCA) (DSP-1747) (formerly INT-747, 6ECDCA) Business: Hepatic …

    Published on 3/30/2015
  • Opicapone: Phase III data

    Bial-Portela & Ca. S.A., S. Mamede do Coronado, Portugal Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: Opicapone (BIA 9-1067) Business: Neurology Molecular target: Catechol-O-methyl-transferase (COMT) …

    Published on 3/30/2015
  • Otezla apremilast: Phase IIIb data

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: Otezla apremilast (CC-10004) Business: Autoimmune Molecular target: Phosphodiesterase-4 (PDE-4); Interleukin-2 (IL-2) Description: Oral phosphodiesterase-4 (PDE-4) …

    Published on 3/30/2015
  • Pracinostat: Phase II data

    MEI Pharma Inc. (NASDAQ:MEIP), San Diego, Calif. Product: Pracinostat (formerly SB939) Business: Cancer Molecular target: Histone deacetylase (HDAC) Description: Class I, II and IV oral histone deacetylase (HDAC) …

    Published on 3/30/2015
  • Prostate cancer liquid biopsy test: Clinical trial data

    Exosome Diagnostics Inc., Cambridge, Mass. Product: Prostate cancer liquid biopsy test Business: Diagnostic Molecular target: NA Description: Non-invasive, urine-based liquid biopsy prostate cancer test that analyzes …

    Published on 3/30/2015
  • Squalamine eye drops: Phase II final data

    Ohr Pharmaceutical Inc. (NASDAQ:OHRP), Salt Lake City, Utah Product: Squalamine eye drops (OHR-102) Business: Ophthalmic Molecular target: Calmodulin Description: Topical eye drop formulation of the synthetic small …

    Published on 3/30/2015
  • StrataGraft: Phase Ib data

    Stratatech Corp., Madison, Wis. Product: StrataGraft Business: Dermatology Molecular target: NA Description: Second-generation cell-based, tissue-engineered human skin substitute developed using NIKS human keratinocytes…

    Published on 3/30/2015
  • Tivozanib: Phase II final data

    Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Cambridge, Mass. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: Tivozanib (ASP4130, AV-951) (formerly KRN951) Business: Cancer Molecular target: Vascular …

    Published on 3/30/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993